Turn Therapeutics (NASDAQ:TTRX) Stock Moved Down to “Sell” by Wall Street Zen

Wall Street Zen lowered shares of Turn Therapeutics (NASDAQ:TTRX) from a hold rating to a sell rating in a research report released on Sunday morning,Wall Street Zen reports.

Other equities analysts also recently issued reports about the company. Weiss Ratings downgraded Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th. WBB Securities upgraded Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 target price on the stock in a research report on Friday, October 23rd. Zacks Research raised Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. Finally, Lucid Cap Mkts upgraded Turn Therapeutics to a “strong-buy” rating in a research report on Thursday, September 24th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Turn Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Turn Therapeutics Stock Performance

Shares of NASDAQ:TTRX opened at $9.48 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. The company’s 50-day moving average price is $11.70 and its 200 day moving average price is $7.13. The company has a market cap of $289.42 million and a PE ratio of -32.69. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $16.45.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Sell-side analysts anticipate that Turn Therapeutics will post -0.40 earnings per share for the current year.

Hedge Funds Weigh In On Turn Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TTRX. Ieq Capital LLC bought a new stake in shares of Turn Therapeutics during the 2nd quarter worth about $1,660,000. Bridgewater Advisors Inc. acquired a new stake in shares of Turn Therapeutics in the 2nd quarter worth approximately $242,000. SteelPeak Wealth LLC lifted its stake in shares of Turn Therapeutics by 0.7% in the 3rd quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock worth $3,616,000 after acquiring an additional 1,819 shares during the period. TD Waterhouse Canada Inc. bought a new position in shares of Turn Therapeutics in the third quarter valued at approximately $40,000. Finally, Bank of America Corp DE bought a new position in shares of Turn Therapeutics in the second quarter valued at approximately $103,000.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.